Efficacy and survival of infliximab in psoriasis patients: A single‐center experience in China

By Chen W, Ding Y, Lu J, et al
Published August 26, 2020

Key Takeaways

Researchers tested infliximab in terms of survival and discontinuation rates in psoriasis patients in real‐world settings in China. This retrospective analysis involved patients with moderate‐to‐severe psoriasis managed with infliximab in Shanghai Skin Disease Hospital from January 2015 to April 2020. Patients included in this study were 42 in total (38.1% had been diagnosed with psoriatic arthritis [PsA]). A discontinuation rate of 57.1% was reported, and the mean survival time of discontinuation was 57 weeks vs 69 weeks for patients with PsA vs those without PsA, respectively. As per Cox regression analysis, longer survival of infliximab was observed in relation to cholesterol level and lymphocyte percentage. Overall, compared with previous studies, a similar drug survival was reported for infliximab in this study. Experts suggested a likely role of high cholesterol level and lymphocyte percentage as negative predictor for infliximab persistence.

Read the full article on Dermatologic Therapy.

Share with emailShare to FacebookShare to LinkedInShare to Twitter